Targeting the CD74-MHC II axis with allergen-specific immunotherapy ameliorates pollen-induced allergic asthma.
- 1Allergy Department, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
- 2Allergy Research Institute, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
- 3Beijing Institute of Medical Device Testing, Beijing, 101111, China.
Abstract
The incidence and prevalence of allergic asthma are increasing year by year, making it one of the major public health concerns affecting human health. Artemisia annua (A. annua) pollen is a key allergen responsible for allergic asthma in northern China. Allergen-specific immunotherapy (AIT), including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), is an important strategy for the treatment of allergic diseases. The aim of this study was to investigate the effect of A. annua allergen-specific immunotherapy (AIT) on allergic asthma and its potential mechanism. An Artemisia annua-induced allergic asthma mouse model was established by subcutaneous sensitization plus aerosol challenge. Methacholine challenge, Wright-Giemsa, H&E and AB-PAS staining were used to validate the model and assess specific immunotherapy efficacy. Inflammatory factors in bronchoalveolar lavage fluid (BALF) and lung tissues were detected via ELISA and high-throughput Luminex assay. Proteomic analysis explored the potential mechanism of SCIT, with results verified by Western blot and immunofluorescence. Our preclinical data identified CD74-enriched immune cell subsets in human peripheral blood mononuclear cells (PBMCs) by using Flow cytometry. Compared with the control group, asthmatic mice exhibited significantly increased airway hyperresponsiveness, serum IgE, IgG1 and IgG2a levels, BALF inflammatory cell counts, IL-1β and TNF-α secretion, as well as severe peribronchial inflammatory infiltration. Lung tissue expression of IL-5, IL-3, CCL2 and TNF-α was also markedly elevated. Notably, SCIT treatment significantly ameliorated these abnormalities except for serum total IgE, IgG1 and IgG2a. Moreover, SCIT inhibited the asthma-induced upregulation of CD74, MHC-II, CD11c and GATA3, and significantly increased FOXP3 expression.Consistently, flow cytometric analysis of human peripheral blood mononuclear cells (PBMCs) revealed elevated CD74-MHC-II axis expression on plasmacytoid dendritic cells (pDCs) in asthmatic participants, with a prominent downward tendency observed following SLIT treatment. In conclusion, Artemisia annua pollen-specific immunotherapy alleviates airway inflammation and hyperresponsiveness in allergic asthma and attenuated GATA3-related type 2 inflammation, possibly in association with inhibition of CD74-MHC-II axis activation within plasmacytoid dendritic cells.
Related
- Allergen Immunotherapy and 36‐Month Allergic Respiratory Disease Trajectories: A Target‐Trial
- CAR-macrophage immunotherapy targeting fibroblast-like synoviocytes ameliorates inflammatory and degenerative arthritis
- Rationally Engineered Self-Assembling Protein Nanoparticles for Allergen-Specific Peanut Allergy Immunotherapy
- Allergen Spectrum and House Dust Mite Component-Resolved Sensitization Patterns in Children with Allergic Rhinitis: A Two-Stage Study.
- Patterns of Allergen Sensitization in Patients with Allergic Disease in Wenzhou, China: A Cross-Sectional Study
BibTeX
@article{ming2026targeting,
title = {{Targeting the CD74-MHC II axis with allergen-specific immunotherapy ameliorates pollen-induced allergic asthma.}},
author = {Wenhua Ming and Yang Zhou and Tingting Liu and Hongtian Wang and Xueyan Wang and Tingting Ma},
journal = {The World Allergy Organization journal},
year = {2026},
month = oct,
doi = {10.1016/j.waojou.2026.101478},
url = {https://europepmc.org/article/MED/42997062},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Targeting the CD74-MHC II axis with allergen-specific immunotherapy ameliorates pollen-induced allergic asthma.
AU - Wenhua Ming
AU - Yang Zhou
AU - Tingting Liu
AU - Hongtian Wang
AU - Xueyan Wang
AU - Tingting Ma
PY - 2026
DA - 2026/10/28
JO - The World Allergy Organization journal
DO - 10.1016/j.waojou.2026.101478
UR - https://europepmc.org/article/MED/42997062
AB - The incidence and prevalence of allergic asthma are increasing year by year, making it one of the major public health concerns affecting human health. Artemisia annua (A. annua) pollen is a key allergen responsible for allergic asthma in northern China. Allergen-specific immunotherapy (AIT), including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), is an important strategy for the treatment of allergic diseases. The aim of this study was to investigate the effect of A. annua allergen-specific immunotherapy (AIT) on allergic asthma and its potential mechanism. An Artemisia annua-induced allergic asthma mouse model was established by subcutaneous sensitization plus aerosol challenge. Methacholine challenge, Wright-Giemsa, H&E and AB-PAS staining were used to validate the model and assess specific immunotherapy efficacy. Inflammatory factors in bronchoalveolar lavage fluid (BALF) and lung tissues were detected via ELISA and high-throughput Luminex assay. Proteomic analysis explored the potential mechanism of SCIT, with results verified by Western blot and immunofluorescence. Our preclinical data identified CD74-enriched immune cell subsets in human peripheral blood mononuclear cells (PBMCs) by using Flow cytometry. Compared with the control group, asthmatic mice exhibited significantly increased airway hyperresponsiveness, serum IgE, IgG1 and IgG2a levels, BALF inflammatory cell counts, IL-1β and TNF-α secretion, as well as severe peribronchial inflammatory infiltration. Lung tissue expression of IL-5, IL-3, CCL2 and TNF-α was also markedly elevated. Notably, SCIT treatment significantly ameliorated these abnormalities except for serum total IgE, IgG1 and IgG2a. Moreover, SCIT inhibited the asthma-induced upregulation of CD74, MHC-II, CD11c and GATA3, and significantly increased FOXP3 expression.Consistently, flow cytometric analysis of human peripheral blood mononuclear cells (PBMCs) revealed elevated CD74-MHC-II axis expression on plasmacytoid dendritic cells (pDCs) in asthmatic participants, with a prominent downward tendency observed following SLIT treatment. In conclusion, Artemisia annua pollen-specific immunotherapy alleviates airway inflammation and hyperresponsiveness in allergic asthma and attenuated GATA3-related type 2 inflammation, possibly in association with inhibition of CD74-MHC-II axis activation within plasmacytoid dendritic cells.
SN - 1939-4551
ER -